Model AZD4573 Phase I -Haematalogical malignancies

Mechanism: CDK9 inhibitor Area under investigation: haematalogical malignancies Date commenced phase: Q4 2017 Estimated Filing Acceptance: US: EU: Japan: China. Additional information. Molecule size: Small molecule Status change: New to Phase II.